Skip Nav Destination
Modern Trends in Psychiatry
New Directions in Tardive Dyskinesia ResearchAvailable to Purchase
Edited by
S.Karger AG
Volume
21
Status:
Available
ISBN electronic:
978-3-318-03976-4
ISBN print:
978-3-8055-3735-3
Book Series:
Modern Trends in Psychiatry
Published online:
2015
Published in print:
1983
New Directions in Tardive Dyskinesia Research
Edited by: J. Bannet, R.H. Belmaker
https://doi.org/10.1159/isbn.978-3-318-03976-4
ISBN (print): 978-3-8055-3735-3
ISBN (electronic): 978-3-318-03976-4
Publisher: S.Karger AG
Published: 1983
Download citation file:
Digital Version
Pay-Per-View Access
$148.00
Print Version
New Directions in Tardive Dyskinesia Research
$148.00
Table of Contents
-
1 - 4: IntroductionByJ. Bannet;J. BannetJerusalem Mental Health Center-Ezrath Nashim, Psychiatric Hospital, Jerusalem, IsraelSearch for other works by this author on:R. H. BelmakerR. H. BelmakerJerusalem Mental Health Center-Ezrath Nashim, Psychiatric Hospital, Jerusalem, IsraelSearch for other works by this author on:
-
5 - 20: Animal Models of Tardive Dyskinesia: Their Use in the Search for New Treatment MethodsByChristopher G. Goetz;Christopher G. GoetzDepartment of Neurological Sciences, Rush-Presbyterian St. Lukes Medical Center, Chicago, Ill., USASearch for other works by this author on:Harold L. Klawans;Harold L. KlawansDepartment of Neurological Sciences, Rush-Presbyterian St. Lukes Medical Center, Chicago, Ill., USASearch for other works by this author on:Paul CarveyPaul CarveyDepartment of Neurological Sciences, Rush-Presbyterian St. Lukes Medical Center, Chicago, Ill., USASearch for other works by this author on:
-
21 - 33: Monkey Models of Tardive Dyskinesia1ByEdward F. Domino;Edward F. DominoLafayette Clinic, Detroit, and University of Michigan, Ann Arbor, Mich., USASearch for other works by this author on:Beverly KovacicBeverly KovacicLafayette Clinic, Detroit, and University of Michigan, Ann Arbor, Mich., USASearch for other works by this author on:
-
34 - 48: Reversible Tardive Dyskinesia: Implications for Therapeutic Strategy and Prevention of Tardive DyskinesiaByDilip V. Jeste;Dilip V. JesteaAdult Psychiatry Branch, National Institute of Mental Health, Intramural Research Program, Saint Elizabeths Hospital, Washington, D.C., USA;Search for other works by this author on:Sonali D. Jeste;Sonali D. JestebDepartment of Child Psychiatry, J.F. Kennedy Institute, Johns Hopkins University Hospital, Baltimore, Md., USASearch for other works by this author on:Richard Jed WyattRichard Jed WyattaAdult Psychiatry Branch, National Institute of Mental Health, Intramural Research Program, Saint Elizabeths Hospital, Washington, D.C., USA;Search for other works by this author on:
-
49 - 64: Neuroleptic Classification: Implications for Tardive DyskinesiaByJohn Hyttel;John HyttelDepartment of Pharmacology and Toxicology, H. Lundbeck & Co. A/S, Copenhagen-Valby, DenmarkSearch for other works by this author on:Anne Vibeke Christensen;Anne Vibeke ChristensenDepartment of Pharmacology and Toxicology, H. Lundbeck & Co. A/S, Copenhagen-Valby, DenmarkSearch for other works by this author on:Jørn ArntJørn ArntDepartment of Pharmacology and Toxicology, H. Lundbeck & Co. A/S, Copenhagen-Valby, DenmarkSearch for other works by this author on:
-
65 - 79: Neuroleptic Treatment in Tardive Dyskinesia: Can It Be Developed Into a Clinical Strategy for Long-Term Treatment?1ByL. M. Toenniessen;L. M. ToenniessenbWestern Psychiatric Institute and Clinic, University of Pittsburgh, School of Medicine, Pittsburgh, Pa., USASearch for other works by this author on:D. E. CaseyD. E. CaseyaMedical Research, Psychiatry, and Neurology Services, VA Medical Center, and Oregon Health Sciences University, Portland, Oreg.;Search for other works by this author on:
-
80 - 86: Atypical Neuroleptics: Clozapine and the Benzamides in the Prevention and Treatment of Tardive DyskinesiaByE. H. Pi;E. H. PiaDepartment of Psychiatry, University of Southern California School of Medicine, Los Angeles, Calif, USA;Search for other works by this author on:G. M. SimpsonG. M. SimpsonbDepartment of Psychiatry, Medical College of Pennsylvania at EPPI, Philadelphia, Pa., USASearch for other works by this author on:
-
87 - 96: Dosage and Blood Levels of Neuroleptics in Tardive DyskinesiaByRobert C. Smith;Robert C. SmithSection of Biological Psychiatry, Texas Research Institute of Mental Sciences, Texas Medical Center, Houston, Tex., and Departments of Psychiatry and Pharmacology, Baylor College of Medicine, Houston, Tex., USASearch for other works by this author on:Chandra H. Misra;Chandra H. MisraSection of Biological Psychiatry, Texas Research Institute of Mental Sciences, Texas Medical Center, Houston, Tex., and Departments of Psychiatry and Pharmacology, Baylor College of Medicine, Houston, Tex., USASearch for other works by this author on:Richard Allen;Richard AllenSection of Biological Psychiatry, Texas Research Institute of Mental Sciences, Texas Medical Center, Houston, Tex., and Departments of Psychiatry and Pharmacology, Baylor College of Medicine, Houston, Tex., USASearch for other works by this author on:Jack GordonJack GordonSection of Biological Psychiatry, Texas Research Institute of Mental Sciences, Texas Medical Center, Houston, Tex., and Departments of Psychiatry and Pharmacology, Baylor College of Medicine, Houston, Tex., USASearch for other works by this author on:
-
97 - 110: Dopamine Agonists in Clinical Research for New Tardive Dyskinesia TreatmentsByJ. Gerlach;J. GerlachSct. Hans Hospital, Department H, Roskilde, Denmark, and Medical Research, Psychiatry, and Neurology Services, VA Medical Center and Oregon Health Sciences University, Portland, Oreg., USASearch for other works by this author on:D. E. CaseyD. E. CaseySct. Hans Hospital, Department H, Roskilde, Denmark, and Medical Research, Psychiatry, and Neurology Services, VA Medical Center and Oregon Health Sciences University, Portland, Oreg., USASearch for other works by this author on:
-
111 - 123: Mesolimbic System and Tardive Dyskinesia: New Perspectives for TherapyByA. R. CoolsA. R. CoolsDepartment of Pharmacology, University of Nijmegen, The NetherlandsSearch for other works by this author on:
-
124 - 142: Dopamine Inhibitory and Excitatory Systems in Tardive DyskinesiasByJ. Offermeier;J. OffermeierMRC Research Unit for the Design of Catecholaminergic Drugs, Potchefstroom University, Potchefstroom, South AfricaSearch for other works by this author on:J. M. van RooyenJ. M. van RooyenMRC Research Unit for the Design of Catecholaminergic Drugs, Potchefstroom University, Potchefstroom, South AfricaSearch for other works by this author on:
-
143 - 154: GABA System, GABA Receptor Agonists and DyskinesiaByGiuseppe BartholiniGiuseppe BartholiniResearch and Development, Laboratoires d’Etudes et de Recherches Synthélabo, Paris, FranceSearch for other works by this author on:
-
155 - 167: GABA System: Clinical Research and Treatment of Tardive DyskinesiaByG. K. Thaker;G. K. ThakerMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore, Md., USASearch for other works by this author on:T. A. Hare;T. A. HareMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore, Md., USASearch for other works by this author on:C. A. TammingaC. A. TammingaMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore, Md., USASearch for other works by this author on:
-
168 - 186: Cholinergic Treatments for Tardive DyskinesiaByLarry D. Alphs;Larry D. AlphsDepartment of Psychiatry, University of Chicago Hospitals and Clinics, Chicago and Illinois State Psychiatric Institute and Department of Psychiatry, University of Illinois, Chicago, Ill., USASearch for other works by this author on:John M. DavisJohn M. DavisDepartment of Psychiatry, University of Chicago Hospitals and Clinics, Chicago and Illinois State Psychiatric Institute and Department of Psychiatry, University of Illinois, Chicago, Ill., USASearch for other works by this author on:
-
187 - 195: Peptide Neurotransmitters and Their Implications for the Treatment of Tardive DyskinesiaByIlana Blum;Ilana BlumDepartments of Medicine C and Neurology, Tel Aviv Medical Center, and Department of Physiology and Pharmacology, Tel Aviv University, Sackler School of Medicine, Ramat Aviv, IsraelSearch for other works by this author on:Amos D. KorczynAmos D. KorczynDepartments of Medicine C and Neurology, Tel Aviv Medical Center, and Department of Physiology and Pharmacology, Tel Aviv University, Sackler School of Medicine, Ramat Aviv, IsraelSearch for other works by this author on:
-
196 - 205: Cyclo(Leu-Gly): A Possible Treatment for Tardive Dyskinesia?1ByHemendra N. BhargavaHemendra N. BhargavaDepartment of Pharmacodynamics, College of Pharmacy, Health Sciences Center, University of Illinois at Chicago, Chicago, Ill., USASearch for other works by this author on:
-
206 - 219: Does Tardive Dyskinesia Exist?ByT. J. Crow;T. J. CrowDivision of Psychiatry, Clinical Research Centre, Northwick Park Hospital, Harrow, EnglandSearch for other works by this author on:D. G.C. Owens;D. G.C. OwensDivision of Psychiatry, Clinical Research Centre, Northwick Park Hospital, Harrow, EnglandSearch for other works by this author on:E. C. Johnstone;E. C. JohnstoneDivision of Psychiatry, Clinical Research Centre, Northwick Park Hospital, Harrow, EnglandSearch for other works by this author on:A. J. Cross;A. J. CrossDivision of Psychiatry, Clinical Research Centre, Northwick Park Hospital, Harrow, EnglandSearch for other works by this author on:F. OwenF. OwenDivision of Psychiatry, Clinical Research Centre, Northwick Park Hospital, Harrow, EnglandSearch for other works by this author on:
